Xanamem depression trial published in British J Psychiatry
Open PDF
| Stock | Actinogen Medical Ltd (ACW.ASX) |
|---|---|
| Release Time | 20 Jul 2026, 9:33 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Actinogen Medical Publishes Xanamem Depression Trial Results
Key Points
- Xanamem shows meaningful anti-depressant activity in difficult-to-treat population
- No correlation between cognitive improvement and depression improvement
- Xanamem safe and well-tolerated
Full Summary
Actinogen Medical Limited has announced the publication of results from its phase 2 trial of Xanamem (emestedastat) in the British Journal of Psychiatry. The trial, designed to assess the drug's potential as a novel antidepressant, enrolled 165 participants with major depressive disorder and cognitive impairment. Key findings include meaningful anti-depressant activity, particularly in patients on SSRI medication, and the absence of a correlation between cognitive and depressive symptom improvements. Xanamem demonstrated safety and tolerability, with no significant adverse effects reported.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In